CN103502272B - 识别Tau的磷酸化特异抗体 - Google Patents
识别Tau的磷酸化特异抗体 Download PDFInfo
- Publication number
- CN103502272B CN103502272B CN201180058969.9A CN201180058969A CN103502272B CN 103502272 B CN103502272 B CN 103502272B CN 201180058969 A CN201180058969 A CN 201180058969A CN 103502272 B CN103502272 B CN 103502272B
- Authority
- CN
- China
- Prior art keywords
- antibody
- tau
- amino acid
- seq
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Neurology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Physical Education & Sports Medicine (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10186810 | 2010-10-07 | ||
| EP10186810.7 | 2010-10-07 | ||
| EP11174248.2 | 2011-07-15 | ||
| EP11174248 | 2011-07-15 | ||
| PCT/EP2011/067604 WO2012045882A2 (en) | 2010-10-07 | 2011-10-07 | Pharmaceutical composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103502272A CN103502272A (zh) | 2014-01-08 |
| CN103502272B true CN103502272B (zh) | 2016-06-15 |
Family
ID=44947048
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201180058969.9A Active CN103502272B (zh) | 2010-10-07 | 2011-10-07 | 识别Tau的磷酸化特异抗体 |
Country Status (29)
| Country | Link |
|---|---|
| US (2) | US9304138B2 (enExample) |
| EP (2) | EP2625198B1 (enExample) |
| JP (2) | JP6371526B2 (enExample) |
| KR (1) | KR101988672B1 (enExample) |
| CN (1) | CN103502272B (enExample) |
| AR (1) | AR085198A1 (enExample) |
| AU (1) | AU2011311516B2 (enExample) |
| BR (1) | BR112013008333B1 (enExample) |
| CA (1) | CA2812865C (enExample) |
| CL (1) | CL2013000951A1 (enExample) |
| CO (1) | CO6710903A2 (enExample) |
| CR (1) | CR20130160A (enExample) |
| DK (1) | DK2625198T3 (enExample) |
| EC (1) | ECSP13012609A (enExample) |
| ES (1) | ES2548686T3 (enExample) |
| HK (1) | HK1216897A1 (enExample) |
| HU (1) | HUE027649T2 (enExample) |
| IL (1) | IL225568A (enExample) |
| MX (1) | MX338421B (enExample) |
| MY (1) | MY164376A (enExample) |
| PE (1) | PE20140218A1 (enExample) |
| PH (1) | PH12013500615A1 (enExample) |
| PL (1) | PL2625198T3 (enExample) |
| RU (1) | RU2603078C2 (enExample) |
| SG (1) | SG189136A1 (enExample) |
| SI (1) | SI2625198T1 (enExample) |
| TW (1) | TW201216985A (enExample) |
| WO (1) | WO2012045882A2 (enExample) |
| ZA (1) | ZA201302432B (enExample) |
Families Citing this family (82)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10266585B2 (en) * | 2009-08-28 | 2019-04-23 | The Board Of Regents Of The Univerity Of Texas System | Methods of treating brain injury |
| US10130697B2 (en) | 2010-03-23 | 2018-11-20 | Wisconsin Alumni Research Foundation (Warf) | Vaccines comprising mutant attenuated influenza viruses |
| RU2603078C2 (ru) * | 2010-10-07 | 2016-11-20 | Ац Иммуне С.А. | Фармацевтическая композиция |
| TR201812636T4 (tr) | 2010-10-11 | 2018-09-21 | Biogen Int Neuroscience Gmbh | İnsan anti-tau antikorları. |
| US20120244174A1 (en) | 2011-01-31 | 2012-09-27 | Intellect Neurosciences Inc. | Treatment of tauopathies |
| GB201112056D0 (en) | 2011-07-14 | 2011-08-31 | Univ Leuven Kath | Antibodies |
| US10813630B2 (en) | 2011-08-09 | 2020-10-27 | Corquest Medical, Inc. | Closure system for atrial wall |
| US10307167B2 (en) | 2012-12-14 | 2019-06-04 | Corquest Medical, Inc. | Assembly and method for left atrial appendage occlusion |
| US10314594B2 (en) | 2012-12-14 | 2019-06-11 | Corquest Medical, Inc. | Assembly and method for left atrial appendage occlusion |
| EP2747778B1 (en) | 2011-08-26 | 2017-12-06 | Wisconsin Alumni Research Foundation | Influenza viruses with mutant pb2 gene segment as live attenuated vaccines |
| CN108034005B (zh) * | 2011-10-07 | 2021-06-25 | Ac免疫有限公司 | 识别Tau的磷酸化特异抗体 |
| NZ626269A (en) | 2011-12-20 | 2016-06-24 | Janssen Biotech Inc | Anti-phf-tau antibodies and their uses |
| WO2013151762A1 (en) * | 2012-04-05 | 2013-10-10 | Ac Immune S.A. | Humanized tau antibody |
| EP3838921A3 (en) * | 2012-07-03 | 2021-09-01 | Washington University | Antibodies to tau |
| WO2014016737A1 (en) * | 2012-07-24 | 2014-01-30 | Pfizer Inc. | Novel chicken monoclonal antibodies against human phosphorylated tau and uses thereof |
| NZ630542A (en) | 2012-08-16 | 2017-06-30 | Ipierian Inc | Methods of treating a tauopathy |
| WO2014043480A1 (en) | 2012-09-13 | 2014-03-20 | Crystal Ronald G | Treatment of brain cancers using central nervous system mediated gene transfer of monoclonal antibodies |
| US20140142689A1 (en) | 2012-11-21 | 2014-05-22 | Didier De Canniere | Device and method of treating heart valve malfunction |
| CA2896066C (en) | 2012-12-21 | 2022-07-12 | Biogen Ma Inc. | Human anti-tau antibodies |
| US8980270B2 (en) | 2013-01-18 | 2015-03-17 | Ipierian, Inc. | Methods of treating a tauopathy |
| RU2661111C2 (ru) * | 2013-03-15 | 2018-07-11 | Ац Иммуне С.А. | Антитела к тау и способы применения |
| JP6824735B2 (ja) | 2013-06-06 | 2021-02-03 | ピエール、ファーブル、メディカマン | 抗Ｃ１０ｏｒｆ５４抗体およびその使用方法 |
| GB201312226D0 (en) * | 2013-07-08 | 2013-08-21 | Adx Neurosciences | Improved antibodies |
| US9566443B2 (en) | 2013-11-26 | 2017-02-14 | Corquest Medical, Inc. | System for treating heart valve malfunction including mitral regurgitation |
| MX384909B (es) * | 2013-11-27 | 2025-03-14 | Ipierian Inc | Un anticuerpo anti-tau para usarse al tratar una tauopatía. |
| ES2778498T3 (es) | 2013-12-20 | 2020-08-10 | Hoffmann La Roche | Anticuerpos anti-tau(pS422) humanizados y procedimientos de uso |
| US10400018B2 (en) * | 2014-02-14 | 2019-09-03 | Ipierian, Inc. | Tau peptides, anti-tau antibodies, and methods of use thereof |
| WO2015196150A2 (en) | 2014-06-20 | 2015-12-23 | Wisconsin Alumni Research Foundation (Warf) | Mutations that confer genetic stability to additional genes in influenza viruses |
| AR100978A1 (es) | 2014-06-26 | 2016-11-16 | Hoffmann La Roche | LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS |
| TWI734975B (zh) | 2014-06-27 | 2021-08-01 | 美商Ｃ２Ｎ醫療診斷有限責任公司 | 人類化抗-tau抗體 |
| EP3760235A1 (en) | 2014-09-30 | 2021-01-06 | Washington University | Tau kinetic measurements |
| SMT202100055T1 (it) * | 2014-11-19 | 2021-03-15 | Axon Neuroscience Se | Anticorpi tau umanizzati nella malattia di alzheimer |
| US10842626B2 (en) | 2014-12-09 | 2020-11-24 | Didier De Canniere | Intracardiac device to correct mitral regurgitation |
| JO3576B1 (ar) | 2015-02-26 | 2020-07-05 | Lilly Co Eli | أجسام مضادة لـ tau واستخداماتها |
| PL3303386T3 (pl) | 2015-06-05 | 2025-03-03 | Genentech, Inc. | Przeciwciała anty-tau i sposoby zastosowania |
| EP3744732B1 (en) | 2015-06-24 | 2025-09-10 | F. Hoffmann-La Roche AG | Humanized anti-tau(ps422) antibodies and methods of use |
| WO2017005734A1 (en) | 2015-07-06 | 2017-01-12 | Ucb Biopharma Sprl | Tau-binding antibodies |
| JO3711B1 (ar) * | 2015-07-13 | 2021-01-31 | H Lundbeck As | أجسام مضادة محددة لبروتين تاو وطرق استعمالها |
| EP3334761B1 (en) * | 2015-08-13 | 2023-07-19 | New York University | Antibody-based molecules selective for the {p}ser404 epitope of tau and their uses in the diagnosis and treatment of tauopathy |
| AU2017221444B2 (en) | 2016-02-19 | 2021-07-29 | Wisconsin Alumni Research Foundation (Warf) | Improved influenza B virus replication for vaccine development |
| MA56165A (fr) * | 2016-07-12 | 2022-04-20 | H Lundbeck As | Anticorps spécifiques de la protéine tau hyperphosphorylée et leurs procédés d'utilisation |
| WO2018031361A2 (en) | 2016-08-09 | 2018-02-15 | Eli Lilly And Company | Combination therapy |
| CA3045294A1 (en) | 2016-12-07 | 2018-06-14 | Genentech, Inc. | Anti-tau antibodies and methods of use |
| TWI787219B (zh) | 2016-12-07 | 2022-12-21 | 美商建南德克公司 | 抗-ｔａｕ抗體及使用方法 |
| CN110267985B (zh) * | 2017-01-04 | 2023-05-23 | H.隆德贝克有限公司 | 用于治疗眼科疾病的特异性针对过度磷酸化τ蛋白的抗体 |
| WO2018152359A1 (en) | 2017-02-17 | 2018-08-23 | Denali Therapeutics Inc. | Anti-tau antibodies and methods of use thereof |
| JP2018139530A (ja) | 2017-02-27 | 2018-09-13 | 帝人ファーマ株式会社 | 認知症治療又は予防のためのヒト化抗体及びその製造方法、並びにそれを用いた認知症治療剤又は予防剤 |
| EA039569B1 (ru) * | 2017-03-14 | 2022-02-11 | Х. Лундбекк А/С | Антитела, специфичные к гиперфосфорилированному тау-белку, и способы их применения |
| JOP20180021A1 (ar) | 2017-03-16 | 2019-01-30 | Janssen Biotech Inc | الأجسام المضادة لتكتلات خيوط بروتين تاو (tau) الحلزونية المزدوجة واستخداماتها |
| WO2018217630A1 (en) * | 2017-05-21 | 2018-11-29 | University Of Tennessee Research Foundation | Methods and compositions for targeting tissue lesions |
| PE20210115A1 (es) | 2017-10-16 | 2021-01-19 | Eisai Randd Man Co Ltd | Anticuerpos anti-tau y uso de los mismos |
| JP2021500891A (ja) | 2017-10-25 | 2021-01-14 | ウィスコンシン アルムニ リサーチ ファンデイション | 卵における複製のための安定化されたｈａを有する組換えインフルエンザウイルス |
| JP7267606B2 (ja) * | 2017-11-28 | 2023-05-02 | 国立大学法人三重大学 | 検出方法 |
| EA202092088A1 (ru) | 2018-03-05 | 2020-11-13 | Янссен Фармацевтика Нв | Антитела анти-phf-тау и их применение |
| JP2021530552A (ja) | 2018-07-31 | 2021-11-11 | イーライ リリー アンド カンパニー | 併用療法 |
| US12343390B2 (en) | 2018-08-07 | 2025-07-01 | Wisconsin Alumni Research Foundation (Warf) | Recombinant biologically contained filovirus vaccine |
| JP7655849B2 (ja) | 2018-08-20 | 2025-04-02 | ウィスコンシン アルムニ リサーチ ファンデイション | ヘマグルチニン（ｈａ）タンパク質内の非ドミナントエピトープに対する免疫応答を誘起するためのベクター |
| US12116415B2 (en) * | 2018-10-09 | 2024-10-15 | Single Cell Technology, Inc. | Anti-BCMA antibodies |
| WO2020077380A1 (en) * | 2018-10-17 | 2020-04-23 | The University Of Queensland | Methods and compositions for treating tauopathies |
| CA3118692A1 (en) | 2018-11-06 | 2020-05-14 | Alsatech, Inc. | Cell-based gene therapy for neurodegenerative diseases |
| CN113543808A (zh) * | 2019-01-04 | 2021-10-22 | 特瑞奥制药公司 | 多特异性蛋白质分子及其用途 |
| US11851648B2 (en) | 2019-02-08 | 2023-12-26 | Wisconsin Alumni Research Foundation (Warf) | Humanized cell line |
| JP7748876B2 (ja) | 2019-04-05 | 2025-10-03 | タウク３ バイオロジクス リミテッド | 抗タウｃ３抗体及びその使用 |
| EP3953392A1 (en) * | 2019-04-12 | 2022-02-16 | Phanes Therapeutics, Inc. | Humanized anti-folate receptor 1 chimeric antigen receptors and uses thereof |
| WO2020223699A1 (en) | 2019-05-01 | 2020-11-05 | Wisconsin Alumni Research Foundation (Warf) | Improved influenza virus replication for vaccine development |
| CN110028583B (zh) * | 2019-05-07 | 2020-09-11 | 温州医科大学 | 抗Tau抗体及其在治疗阿尔茨海默病、创伤性脑损伤中的应用 |
| US11807872B2 (en) | 2019-08-27 | 2023-11-07 | Wisconsin Alumni Research Foundation (Warf) | Recombinant influenza viruses with stabilized HA for replication in eggs |
| CN112752251B (zh) | 2019-10-29 | 2022-05-06 | 中国移动通信有限公司研究院 | 一种ue标识符的分配方法、装置和计算机可读存储介质 |
| WO2021150874A1 (en) | 2020-01-24 | 2021-07-29 | Wisconsin Alumni Research Foundation (Warf) | Recombinant influenza viruses with stabilized na |
| MX2022009607A (es) * | 2020-02-05 | 2022-09-02 | Sumitomo Pharma Co Ltd | Agente de determinacion y metodo de determinacion de taupatia y enfermedades relacionadas con la demencia. |
| US12290562B2 (en) | 2020-03-25 | 2025-05-06 | Wisconsin Alumni Research Foundation (Warf) | Recombinant multivalent influenza viruses |
| WO2021262791A1 (en) | 2020-06-25 | 2021-12-30 | Merck Sharp & Dohme Corp. | High affinity antibodies targeting tau phosphorylated at serine 413 |
| EP4014997A1 (en) | 2020-12-16 | 2022-06-22 | Consejo Superior de Investigaciones Científicas (CSIC) | Stard1 inhibitors for the treatment of lysosomal disorders |
| WO2022132923A1 (en) * | 2020-12-16 | 2022-06-23 | Voyager Therapeutics, Inc. | Tau binding compounds |
| IL305666A (en) * | 2021-03-18 | 2023-11-01 | Seagen Inc | Anti-ALPP/ALPPL2 antibodies and antibody-drug conjugates |
| CL2021001380A1 (es) | 2021-05-26 | 2022-01-14 | Corporacion Centro Int De Biomedicina Icc | Generación de un nuevo anticuerpo monoclonal sitio específico para la proteína tau y su uso como herramienta en biomarcadores específicos para la detección temprana de enfermedades neurodegenerativas y patologías involucradas con la proteína tau como alzheimer y otras demencias. |
| US20250034559A1 (en) | 2021-11-17 | 2025-01-30 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of tau-related disorders |
| CN120019071A (zh) | 2022-09-15 | 2025-05-16 | 沃雅戈治疗公司 | Tau结合化合物 |
| WO2024163923A2 (en) * | 2023-02-02 | 2024-08-08 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Phosphomimetic mutants, phosphospecific antibodies, and uses thereof |
| WO2025122634A1 (en) | 2023-12-05 | 2025-06-12 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of tau-related disorders |
| WO2025128975A1 (en) * | 2023-12-14 | 2025-06-19 | Immunitas Therapeutics, Inc. | Cd161 binding proteins and related methods |
| WO2025134068A1 (en) | 2023-12-22 | 2025-06-26 | Ac Immune Sa | Antibody drug conjugates targeting proteinopathies, and uses thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010106127A2 (en) * | 2009-03-18 | 2010-09-23 | Ac Immune S.A. | Method for therapeutic use |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5004697A (en) | 1987-08-17 | 1991-04-02 | Univ. Of Ca | Cationized antibodies for delivery through the blood-brain barrier |
| US5112596A (en) | 1990-04-23 | 1992-05-12 | Alkermes, Inc. | Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability |
| US5268164A (en) | 1990-04-23 | 1993-12-07 | Alkermes, Inc. | Increasing blood-brain barrier permeability with permeabilizer peptides |
| DE69233767D1 (de) | 1991-12-06 | 2009-09-17 | Max Planck Gesellschaft | Verwendung von Protein-Kinasen zur Diagnose und Behandlung der Alzheimer-Krankheit |
| DE69328430T2 (de) | 1992-07-27 | 2001-01-25 | The Government Of The United States Of America As Represented By The Secretary Of National Institute Of Health, Office Of Technology Transfer | Zielgerichte liposome zur blut-hirne schranke |
| ES2176342T5 (es) | 1994-10-21 | 2010-02-09 | Innogenetics N.V. | Secuencias del genotipo 7 del virus de la hepatitis c y su utilizacion como agentes profilacticos, terapeuticos y de diagnosticos. |
| US5756662A (en) | 1995-03-14 | 1998-05-26 | Corixa Corporation | Compounds and methods for the detection of T. cruzi infection |
| US20020086009A1 (en) * | 1996-03-13 | 2002-07-04 | Koichi Ishiguro | Anti-phosphorylated tau protein antibodies and methods for detecting alzheimer`s disease with the use of the same |
| WO1998022120A1 (en) * | 1996-11-19 | 1998-05-28 | The Wistar Institute Of Anatomy & Biology | Diagnostic and therapeutic reagents for alzheimer's disease |
| JP2004503747A (ja) * | 2000-07-11 | 2004-02-05 | モレキュラー ジェリアトリクス コーポレイション | 結合物質の同定するための試薬と方法 |
| US6514221B2 (en) | 2000-07-27 | 2003-02-04 | Brigham And Women's Hospital, Inc. | Blood-brain barrier opening |
| AU2001286930A1 (en) | 2000-08-30 | 2002-03-13 | The Board Of Trustees Of The Leland Stanford Junior University | Glucocorticoid blocking agents for increasing blood-brain barrier permeability |
| US7034036B2 (en) | 2000-10-30 | 2006-04-25 | Pain Therapeutics, Inc. | Inhibitors of ABC drug transporters at the blood-brain barrier |
| US20030083299A1 (en) | 2000-11-04 | 2003-05-01 | Ferguson Ian A. | Non-invasive delivery of polypeptides through the blood-brain barrier |
| DE10121982B4 (de) | 2001-05-05 | 2008-01-24 | Lts Lohmann Therapie-Systeme Ag | Nanopartikel aus Protein mit gekoppeltem Apolipoprotein E zur Überwindung der Blut-Hirn-Schranke und Verfahren zu ihrer Herstellung |
| JP4202250B2 (ja) | 2001-07-25 | 2008-12-24 | バイオマリン ファーマシューティカル インコーポレイテッド | 血液脳関門輸送を調節するための組成物および方法 |
| US20030162695A1 (en) | 2002-02-27 | 2003-08-28 | Schatzberg Alan F. | Glucocorticoid blocking agents for increasing blood-brain barrier permeability |
| CN101284136A (zh) | 2002-12-03 | 2008-10-15 | 布朗歇特洛克菲勒神经科学研究所 | 传输物质穿过血脑屏障的人工低密度脂蛋白载体 |
| JP2006512417A (ja) | 2002-12-24 | 2006-04-13 | ニューロケム （インターナショナル） リミテッド | β−アミロイド関連疾患の治療のための治療用製剤 |
| JP2007505142A (ja) | 2003-09-10 | 2007-03-08 | セダーズ−シナイ メディカル センター | 血液脳関門を通過する薬剤のカリウムチャネル媒介性送達 |
| US7238788B2 (en) * | 2004-02-18 | 2007-07-03 | University Of Iowa Foundation | Antibodies to phosphorylated tau, methods of making and methods of use |
| NZ554725A (en) | 2004-10-25 | 2009-10-30 | Merck & Co Inc | Anti-ADDL antibodies and uses thereof |
| US8012936B2 (en) * | 2006-03-29 | 2011-09-06 | New York University | Tau fragments for immunotherapy |
| WO2008140639A2 (en) * | 2007-02-08 | 2008-11-20 | Oligomerix, Inc. | Biomarkers and assays for alzheimer's disease |
| EP2522351B1 (en) | 2007-06-13 | 2017-09-06 | Research Development Foundation | Treatment and prevention of tauopathies and amyloid beta amyloidosis by modulating CRF receptor signaling |
| CN101965365A (zh) | 2007-10-19 | 2011-02-02 | 伊缪纳斯制药株式会社 | 能够特异性结合Aβ寡聚体的抗体及其应用 |
| UA107571C2 (xx) * | 2009-04-03 | 2015-01-26 | Фармацевтична композиція | |
| EP2440234A4 (en) * | 2009-06-10 | 2013-11-06 | Univ New York | IMMUNOLOGICAL AIMING OF PATHOLOGICAL TAU PROTEINS |
| NZ598356A (en) | 2009-07-30 | 2014-06-27 | Pfizer Vaccines Llc | Antigenic tau peptides and uses thereof |
| RU2603078C2 (ru) * | 2010-10-07 | 2016-11-20 | Ац Иммуне С.А. | Фармацевтическая композиция |
-
2011
- 2011-10-07 RU RU2013120544/10A patent/RU2603078C2/ru active
- 2011-10-07 CN CN201180058969.9A patent/CN103502272B/zh active Active
- 2011-10-07 BR BR112013008333-6A patent/BR112013008333B1/pt active IP Right Grant
- 2011-10-07 JP JP2013532226A patent/JP6371526B2/ja active Active
- 2011-10-07 EP EP11773704.9A patent/EP2625198B1/en active Active
- 2011-10-07 EP EP15177523.6A patent/EP2987807A3/en not_active Withdrawn
- 2011-10-07 PL PL11773704T patent/PL2625198T3/pl unknown
- 2011-10-07 CA CA2812865A patent/CA2812865C/en active Active
- 2011-10-07 US US13/500,608 patent/US9304138B2/en active Active
- 2011-10-07 MY MYPI2013700539A patent/MY164376A/en unknown
- 2011-10-07 SI SI201130615T patent/SI2625198T1/sl unknown
- 2011-10-07 AU AU2011311516A patent/AU2011311516B2/en active Active
- 2011-10-07 PH PH1/2013/500615A patent/PH12013500615A1/en unknown
- 2011-10-07 WO PCT/EP2011/067604 patent/WO2012045882A2/en not_active Ceased
- 2011-10-07 SG SG2013023031A patent/SG189136A1/en unknown
- 2011-10-07 MX MX2013003800A patent/MX338421B/es active IP Right Grant
- 2011-10-07 PE PE2013000800A patent/PE20140218A1/es not_active Application Discontinuation
- 2011-10-07 DK DK11773704.9T patent/DK2625198T3/en active
- 2011-10-07 HU HUE11773704A patent/HUE027649T2/en unknown
- 2011-10-07 TW TW100136670A patent/TW201216985A/zh unknown
- 2011-10-07 ES ES11773704.9T patent/ES2548686T3/es active Active
- 2011-10-07 KR KR1020137011715A patent/KR101988672B1/ko active Active
- 2011-10-11 AR ARP110103735A patent/AR085198A1/es unknown
-
2013
- 2013-03-04 ZA ZA2013/02432A patent/ZA201302432B/en unknown
- 2013-04-04 IL IL225568A patent/IL225568A/en active IP Right Grant
- 2013-04-05 CR CR20130160A patent/CR20130160A/es unknown
- 2013-04-05 CO CO13089514A patent/CO6710903A2/es unknown
- 2013-04-08 CL CL2013000951A patent/CL2013000951A1/es unknown
- 2013-05-07 EC ECSP13012609 patent/ECSP13012609A/es unknown
-
2016
- 2016-02-17 US US15/045,804 patent/US10100104B2/en active Active
- 2016-04-25 HK HK16104710.3A patent/HK1216897A1/en unknown
-
2017
- 2017-01-20 JP JP2017008740A patent/JP2017113004A/ja active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010106127A2 (en) * | 2009-03-18 | 2010-09-23 | Ac Immune S.A. | Method for therapeutic use |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103502272B (zh) | 识别Tau的磷酸化特异抗体 | |
| CN104080806B (zh) | 识别Tau的磷酸化特异抗体 | |
| JP6293731B2 (ja) | ヒト化タウ抗体 | |
| AU2013205313B2 (en) | Phosphospecific antibodies recognising tau | |
| AU2016202289A1 (en) | Phosphospecific antibodies recognising tau | |
| HK1187928B (en) | Antibodies recognising phospho-tau | |
| HK1200469B (en) | Phosphospecific antibodies recognising tau | |
| HK1209137B (zh) | 人源化tau抗體 | |
| TW201321409A (zh) | 醫藥組合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |